IONIQ Vision
IONIQ envisions a world where your annual check-up includes a Multi-Cancer Screen.
In just 20 minutes, you could know – with no needles, no radiation and no surgery.
We envision a world where cancer is no longer feared – where it is readily treatable and no longer a financial burden. We will do this by making early cancer detection an integral part of annual wellness checks. Lives and money can be saved when cancer is detected at its earliest, most-treatable stages. Early detection is critical and IONIQ Sciences is at the forefront. We will not be satisfied until the scourge of cancer has been eliminated
IONIQ Digital Platform
The world needs early cancer detection: 69% of all cancers are diagnosed in later stages when survival is dramatically lower due to shortcomings from today’s standard of care.
And IONIQ dramatically out-performs today’s standard of care.
Cancer causes an over-sized physiological reaction in the earliest, most-treatable stages of the disease and IONIQ detects that change. Your body’s electrical properties change due to the presence of cancer. The IONIQ System collects up to 13,125 data points as it measures these changes to determine the presence of cancer. By operating at the confluence of Electrical Impedance Analytics (EIA) or bioimpedance and Artificial Intelligence (AI), we believe our cutting-edge IONIQ System can non-invasively scan for cancer in the earliest stages of the disease.
Our growing clinical evidence library already spans 7 trials at 25 premier cancer institutions across 3 continents yielding more than 20 million data points.
IONIQ Pipeline
IONIQ Sciences is following a strategic course to modernize early stage cancer detection with the first ever FDA cleared Multi-Cancer Screen.
The first step on our quest to early detection at the point-of-care is commercializing our IONIQ ProLung Test, which has been designated a ‘Breakthrough Device‘ by the US FDA for its life-enhancing potential. We will then commercialize our IONIQ Breast Test, which is already in the later phases of feasibility testing.
By following the principles of scientific process, IONIQ Sciences will amass vast amounts of valuable clinical data to develop and commercialize the first ever FDA cleared Multi-Cancer Screen.
IONIQ Team
IONIQ Sciences has a growing and deeply passionate team of problem solvers focused on the early detection of cancer.
We have all been affected by the cold realities of cancer. At IONIQ, we have decided that it does not have to be that way any longer. We will continue our efforts to change the cancer landscape by conquering the challenges of early detection. We have harnessed our ambition to make a lasting contribution to the world.